PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Toronto Region Research Alliance (TRRA)

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Intellectual Capital and Strong Economy Attract Life Sciences Companies Says PwC Report - Toronto's strong, stable economy and depth of intellectual capital are attracting major investment from the world's leading life sciences companies
Intellectual Capital and Strong Economy Attract Life Sciences Companies Says PwC Report

 

NewswireToday - /newswire/ - Toronto, Ontario, Canada, 2011/07/08 - Toronto's strong, stable economy and depth of intellectual capital are attracting major investment from the world's leading life sciences companies.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Ranked #2 overall in the recent PricewaterhouseCoopers (PwC) Cities of Opportunity report, the Toronto Region – the centre of Canada’s life sciences industry – is attracting new research and manufacturing investment from the world’s leading life sciences companies. Toronto also ranks second in intellectual capital and innovation according to the PwC report.

Canada’s economy has out-performed other G7 countries and has experienced a solid recovery. The economy has expanded for six consecutive quarters since the third quarter of 2009, fuelled by a strong rebound in consumer and business expenditures. Canada is the only G-7 country to have regained the output lost over the recession and to have posted significant employment growth since June 2009.(1)

“A strong, stable economy and a vibrant research and innovation environment are important considerations when companies make investment decisions,” says Patrick Draper, President & CEO of the Toronto Region Research Alliance (TRRA). “That’s why the Toronto Region is an attractive location for life sciences companies to invest in global R&D and manufacturing operations.”

Talent is another major draw. In addition to the highly-educated and skilled workforce, over 100,000 immigrants from all corners of the world settle in the Toronto Region each year. “The workforce is smart, talented and globally-oriented, ’ says Draper. “They keep their international perspective and connections which is an advantage for global companies.”

Recent investments include:
• Sanofi Pasteur opened its new $CDN 101 million vaccine research and development facility. As the North American Centre of Excellence in analytical and bioprocessing R&D for Sanofi Pasteur globally, Toronto is playing a lead role in advancing Sanofi Pasteur’s global vaccine pipeline. The Government of Ontario invested $ CDN 13.9 million in this project.
• GlaxoSmithKline Canada announced a $ CDN 30 million expansion to its state-of-the-art advanced manufacturing facility. This expansion will help bring new products to market and enable the global supply of the company's dermatological products. The Government of Ontario will invest $ CDN 3.6 million in this expansion project.
• GE Healthcare opened the first global Pathology Innovation Centre of Excellence (PICOE) in Toronto. The centre will give pathologists and clinical partners the resources to accelerate research and development and testing for new digital pathology solutions. The Health Technology Exchange (HTX), an Ontario government agency, invested $ CDN 2.25 million in this $ CDN 17 million project.

For more information about the Toronto Region and the life sciences sector, visit trra.ca/lifesciences

(1) Source: fin.gc.ca/ec2010/efp-pef-03-eng.asp#a6

About Toronto Region Research Alliance (TRRA)
The Toronto Region Research Alliance (TRRA.ca) is a regional economic development organization promoting increased investment in research and innovation to further economic prosperity. TRRA focuses on retaining and growing foreign investment into regional organizations; attracting innovative, research-intensive foreign companies to locate here; promoting enhanced research intensity among regional businesses; and advancing initiatives to strengthen research and innovation capacity. TRRA is a public-private partnership funded by the government of Ontario and is a key partner in delivering Ontario's Innovation Agenda. TRRA also receives financial support from the government of Canada, and a wide range of regional stakeholders from the private and academic sectors.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Toronto Region Research Alliance (TRRA)

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Intellectual Capital and Strong Economy Attract Life Sciences Companies Says PwC Report

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Ruth Lewkowicz - TRRA.ca 
416-673-6686 rlewkowicz[.]trra.ca
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Toronto Region Research Alliance (TRRA) securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Toronto Region Research Alliance (TRRA) / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)